Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. CytoDyn Inc (CYDY) Message Board

Chess, thanks for sharing the Insider Financial ar

Message Board Public Reply | Private Reply | Keep | Replies (1)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 155392
(Total Views: 737)
Posted On: 04/29/2020 4:03:24 PM
Posted By: KolbeB
Re: chessmaster #30758
Chess, thanks for sharing the Insider Financial article. You're right. The conclusion is my favorite part....
Quote:
Conclusion

These $10 billion lifts on GILD initially from STAT and now Fauci demonstrate what a solution is worth, but remdesivir is not the solution and will not be the “standard of care” despite what Fauci professed to Meg Tirell today. Investors need to see these results through the proper lens. An antiviral is not the solution. The problem stems from the cytokine storm and that is what is killing people. The change in mortality in these “severely ill” patients is not statistically relevant and will not allay peoples fear of dying. The safety profile of remdesivir is manageable with medication and adjustment to the protocol but does that mean we should treat people with a drug that could debilitate people. There is a trade off for quality of life and there is enough information to rationally say that remdesivir is not going to be a panacea for late stage patients and not doing that great of a job getting people out of the hospitals. Currently only one drug exists that can stop mortality, is virtually devoid of side effects, works in days, and completely quiets the cytokine storm and has 40,000 vials waiting for just one person at the administration to stray away from their love affair with remdesivir. If just one White House Press correspondent asked about leronlimab which is made by CytoDyn Inc. (OTCMKTS: CYDY) then perhaps we can turn the tide of the pandemic. The solution is at hand. Prepared to be outraged that results like this are commonplace yet emergency approval of leronlimab is not at hand.



(2)
(0)




CytoDyn Inc (CYDY) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us